Majesco (COOL) and Disney Interactive Collaborate on Upcoming Video Game

EDISON, NJ — (Marketwire) — 01/08/13 — Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of games for the mass market, announced today a relationship with Disney Interactive to start development of original video games based on the animated hit Disney television series Phineas and Ferb.

“We are thrilled to be teaming up with Disney to bring a new Phineas and Ferb game to market across multiple platforms,” said Jesse Sutton, Chief Executive Officer, Majesco Entertainment. “Phineas and Ferb is known for fun-filled adventures and hilarious gags that appeal to a universal audience, and we’re creating a game that leverages the characters and brand attributes of the highly successful series.”

The new game will be developed for retail consoles and gaming handhelds, including smartphones and tablets, and is scheduled for release in August 2013.

For more information on Majesco Entertainment, please visit www.majescoent.com, ‘Like’ us on Facebook or follow the company on Twitter @Majesco.

About Disney Interactive Media Group
Disney Interactive, one of the world’s largest creators of high-quality interactive entertainment across all platforms, is the part of The Walt Disney Company responsible for the global creation and delivery of interactive entertainment, multi-platform video games, and family-focused content across all current and emerging digital media platforms. Disney Interactive produces and distributes a broad portfolio of content from Disney Interactive Games and Disney Interactive Media. Products and content released and operated by Disney Interactive include blockbuster mobile, social and console games, online virtual worlds, #1 kid’s entertainment destination Disney.com and the #1 Family/Parenting portfolio on the Web.

Disney Interactive is the interactive entertainment part of The Walt Disney Company (NYSE: DIS).

About Majesco Entertainment Company
Majesco Entertainment Company is a leading developer and publisher of video games for the mass market. Building on more than 20 years of operating history, the company is focused on developing and publishing a wide range of casual and family oriented video games on all leading console and handheld platforms as well as online, social networks and mobile devices. Product highlights include Zumba® Fitness, Cooking Mama™ and NBA Baller Beats™. The company’s shares are traded on the Nasdaq Stock Market under the symbol: COOL. Majesco is headquartered in Edison, NJ with offices in San Francisco, CA, Brockhampton, UK, and a social games development studio in Foxboro, MA. More info can be found online at majescoent.com or on Twitter @Majesco.

Safe Harbor

Certain statements contained herein are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by reference to a future period(s) or by the use of forward-looking terminology, such as “may,” “will,” “intend,” “should,” “expect,” “anticipate,” “estimate” or “continue” or the negatives thereof or other comparable terminology. The Company’s actual results could differ materially from those anticipated in such forward-looking statements due to a variety of factors. These factors include but are not limited to, the demand for our products; our ability to complete and release our products in a timely fashion; competitive factors in the businesses in which we compete; continued consumer acceptance of our products and the gaming platforms on which our products operate; fulfillment of orders preliminarily made by customers; adverse changes in the securities markets and the availability of and costs associated with sources of liquidity. The Company does not undertake, and specifically disclaims any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Majesco Media Contact:
Tracie Snitker
Reverb Communications
209-586-1495 x104

Planet Payment (PLPM) to Present at the 15th Annual Needham Growth Conference

LONG BEACH, N.Y., Jan. 8, 2013 (GLOBE NEWSWIRE) — Planet Payment, Inc. (Nasdaq:PLPM) (LSE:PPT) (LSE:PPTR), a leading provider of international payment processing and multi-currency processing services, today announced that the Company will present at the 15th Annual Needham Growth Conference at the New York Palace Hotel in New York, N.Y. on Tuesday, January 15, 2013. The presentation will begin at 10:40 AM ET.

Investors and interested parties can access a live presentation by visiting the Company’s investor relations website at http://ir.planetpayment.com at the appropriate time.

About Planet Payment

Planet Payment is a leading provider of international payment processing and multi-currency processing services. We provide our services in 18 countries and territories across the Asia Pacific region, North America, the Middle East, Africa and Europe, primarily through our more than 45 acquiring bank and processor customers. Our point-of-sale and e-commerce services help merchants sell more goods and services to consumers, and together with our ATM services are integrated within the payment card transaction flow enabling our acquiring customers, their merchants and consumers to shop, pay, transact and reconcile payment transactions in multiple currencies, geographies and channels.

Planet Payment is headquartered in New York and has offices in Atlanta, Beijing, Bermuda, Delaware, Dubai, Dublin, London, Hong Kong, Mexico City, Shanghai and Singapore. Visit ww.planetpayment.com for more information about the Company and its services. For up-to-date information follow Planet Payment on Twitter at @PlanetPayment or join Planet Payment’s Facebook page.

CONTACT: Media Relations:

         Planet Payment
         Contact: Robert Cox, CFO
         Telephone: +1.516.670.3200 

         Redleaf Polhill (UK PR for Planet Payment)
         Contacts: Emma Kane / Henry Columbine / David Ison
         Telephone: +44.20.7566.6720
         Email:  planet@redleafpolhill.com

         ICR (US PR for Planet Payment)
         Contacts: Don Duffy / Dara Dierks
         Telephone: +1.646.277.1212

Methes (MEIL) Signs Letter of Intent to Deploy Its Technology in California

LAS VEGAS, NV — (Marketwire) — 01/08/13 — Methes Energies International Ltd. (NASDAQ: MEIL), a renewable energy company that offers an array of products and services to biodiesel fuel producers, announces that its wholly-owned subsidiary, Methes Energies Canada Inc., has signed a Letter of Intent (LOI) with U.S. Energy Initiatives Corp. of Santa Clarita, California (a public company traded under the symbol (PINKSHEETS: USEI)) to initially acquire, among other things, one of our Denami 600 biodiesel processors.

U.S. Energy Initiatives plans to set up its first 1.3 million gallons per year (mgy) production facility in California and use the site as a showcase to market and promote our Denami 600 and Denami 3000 biodiesel processors. Our Denami 600 processors and Denami 3000 processors, respectively, have a maximum rated biodiesel production capacity of 1.3 mgy and 6.5 mgy. The intent is to eventually set up additional facilities in California and across the U.S. as close as possible to feedstock supplies in order to minimize transportation and logistics.

“Our goal is to build a strong biodiesel division using a technology that is already proven and reliable,” said U.S. Energy Initiatives CEO, Anthony Miller. “The Methes business model is truly unique and does not only focus on technology, but also on all of the aspects of biodiesel production and distribution, including product quality, compliance, production, marketing and logistics. Methes’ experience and track record are two strong assets to us that we intend to make the most of.”

Nicholas Ng, President of Methes Energies, said, “We look forward to working with Anthony and his team. They have a comprehensive understanding of biodiesel and a plan to take advantage of the growing demand. With the $1.00 per gallon tax credit back in the U.S., we expect a strong 2013 and beyond.”

About U.S. Energy Initiatives Corp.
U.S. Energy Initiatives Corp, is a diverse energy firm that has a long history of developing automotive and hybrid fuel systems and technologies. This firm started in 1996 and has since become a successful developer of its business strategies. Its Management’s new goal is to also develop new and old technologies, as well as to build a dynamic energy firm. The Company has three separate energy initiatives; one in the oil, gas & technology sector (brought in by Mr. Miller), one in the hybrid fuel or biofuel sector and one in the automotive sector. The firm’s immediate goal is to create its own biofuel opportunities and going forward, to acquire and develop stranded or un-recovered oil properties for enhanced oil production, forming partnerships with operators, in addition to the elaboration of strategic alliances for primary and secondary recovery. The company’s overall goal is to become environmentally responsible in the energy sector, utilizing all of the methods available to create a continued financial growth. Toward achieving that purpose, it will market its products throughout the world to significantly increase revenues, while adding value for its shareholders.

About Methes Energies International Ltd.
Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada and at its recently commissioned 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Registration Statement on Form S-1, filed June 22, 2012, as amended, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:
Methes Energies International Ltd.
Michel G. Laporte
Chairman and CEO
702-932-9964

100K Pathogen Genome Project Selects PacBio (PACB) SMRT® DNA Sequencing

PacBio Long Sequence Reads Provide Ability to Close Genomes; SMRT Kinetic Information Enables Epigenetic Characterization

MENLO PARK, Calif., Jan. 8, 2013 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) provider of the PacBio^®RS High Resolution Genetic Analyzer, and the University of California, Davis (UC Davis) today announced a partnership for the 100K Pathogen Genome Project. As part of the project, Pacific Biosciences’ Single Molecule, Real-Time (SMRT^®) technology will be used to sequence the genomes from at least 1,000 foodborne pathogen samples to completion, and to elucidate their epigenomes. These bacteria represent major illness-causing pathogens, including Salmonella, Campylobacter, E. coli, Vibrio, and Listeria.

The 100K Genome Project was founded by the U.S. Food & Drug Administration, Agilent Technologies, and the laboratory of Dr. Bart Weimer at UC Davis to create a consortium of partners from around the world that will sequence 100,000 foodborne pathogens using next-generation sequencing. This initiative addresses a significant shortage of bacterial pathogen information for use in designing molecular diagnostics, creates a resource to expand our understanding of infection mechanisms, and constructs a public repository for new insights into bacterial evolution by using large-scale genomics.

Pacific Biosciences’ SMRT sequencing technology generates sequence reads an order of magnitude longer than other leading DNA sequencing technologies, thereby facilitating efficient de novo microbial genome assemblies. Long reads are critical for resolving genetic complexity in the assembly and finishing of genomes. The use of SMRT sequencing for the automated finishing of microbial genomes has been demonstrated in multiple recent publications, including for the genetic analysis of the Haitian cholera and German E. coli outbreaks.

The kinetic information acquired during SMRT sequencing can be used to elucidate the epigenome of bacteria. Epigenetic DNA base modifications, such as methylation, play an important role in the phenotypic variation, adaptability and pathogenicity of many bacteria, but they have been difficult to study due to the lack of a sequencing method to detect them. As part of the 100K Genome Project, the epigenomes of the pathogenic strains subjected to SMRT sequencing will be characterized, adding an important dataset to public database repositories.

“SMRT sequencing has been shown to be a powerful technology for the comprehensive determination of microbial genomes and epigenomes,” said Dr. Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. “Through the combination of long reads, high consensus accuracy, and the lack of sequencing bias to GC content or sequence contexts, SMRT sequencing harbors the necessary requirements to construct finished genomes in an unbiased, hypothesis-free manner. The ability to detect methylation as part of the sequencing process is unique to SMRT sequencing, and will provide an invaluable resource to illuminate the epigenetic components controlling bacterial pathogenicity.”

“We are very pleased to utilize SMRT sequencing as part of the 100K Genome Project,” said Bart Weimer, Professor and Director of the 100K Genome Project, “SMRT technology will enable production of complete genomes that will contribute great value toward databases for biological insight, new biomarker discovery, and reference genomes for food pathogen detection. A project of this scale is needed since microbial genome variations, including structural variations, the acquisition and loss of mobile elements, and phages or plasmids, are very difficult or impossible to detect without a de novo sequencing and genome assembly approach, yet they have a significant impact on food safety.”

The partnership will entail the sequencing of at least 1,000 samples by the 100K consortium member labs with access to the PacBio RS instrumentation, including pipeline constructions for high-throughput pathogen sequencing, de novo genome assemblies, epigenome determination, and data curation and deposition. Pacific Biosciences will provide technical guidance and training to support these activities, and interface closely with the involved laboratories to assist in the efficient construction of these pipelines.

For more information, please visit http://100kgenome.vetmed.ucdavis.edu/index.cfm and www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^®RS High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

About The 100K Genome Project

Established in March 2012 by UC Davis, Agilent Technologies and the U.S. Food and Drug Administration, the 100K Genome Project is a landmark consortium that addresses the persistent food safety concerns by engaging world-wide partners to create a publicly available genetic database of the most common foodborne disease-causing microbes. By sequencing 100,000 pathogen genomes, the project will bring a new paradigm to public health to empower precise and robust molecular testing in the food chain – from the farm to the kitchen table. For more information, visit http://100kgenome.vetmed.ucdavis.edu.

About UC Davis

For more than 100 years, UC Davis has engaged in teaching, research and public service that matter to California and transform the world. Located close to the state capital, UC Davis has more than 33,000 students, more than 2,500 faculty and more than 21,000 staff, an annual research budget of nearly $750 million, a comprehensive health system and 13 specialized research centers. The university offers interdisciplinary graduate study and more than 100 undergraduate majors in four colleges — Agricultural and Environmental Sciences, Biological Sciences, Engineering, and Letters and Science. It also houses six professional schools — Education, Law, Management, Medicine, Veterinary Medicine and the Betty Irene Moore School of Nursing.

CONTACT: For Pacific Biosciences:

         Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com

         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com

         For UC Davis:
         Media:
         Patricia Bailey
         Science/Agriculture writer
         UC Davis News Service
         (530) 752-9843 office
         (530) 219-9640 cell
         pjbailey@ucdavis.edu

         Scientific:
         Dr. Bart Weimer
         Professor, School of Veterinary Medicine
         Director, 100K Genome Project
         Director, BGI@UCDavis
         (530) 754-0109
         bcweimer@ucdavis.edu

Acasti Pharma (ACST) Shares to Trade on NASDAQ

LAVAL, Quebec, Jan. 7, 2013 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti“) (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc. (“Neptune“) subsidiary, is pleased to announce that it has been approved to list its common shares on the NASDAQ Capital Market beginning on January 7, 2013 under the ticker symbol “ACST.”

“The listing of our common shares on the NASDAQ is an important milestone for Acasti,” stated Xavier Harland, Chief Financial Officer. “We believe our new listing will provide Acasti greater exposure to investors in the U.S. and around the world and reflects our effort to increase liquidity for our shareholders,” he added.

“We’re completing an important part of Acasti’s development plan with this listing. As set forth in Acasti’s business plan, the NASDAQ listing should be followed by the expected completion of the open label clinical trial,” said Harlan Waksal, Executive Vice-President. “There are multiple US institutional funds that are restricted from investing in shares that trade on foreign exchanges. We therefore believe that Acasti’s NASDAQ listing will broaden its base of potential shareholders,” he added.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

“Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
         Xavier Harland
         Chief Financial Officer
         +1.450.687.2262
         x.harland@acastipharma.com
         www.acastipharma.com

         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com

EntreMed (ENMD) Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ — EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that EntreMed has submitted a new drug clinical trial application with China’s State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients.

(Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Ken K. Ren, Ph.D., EntreMed’s Chief Executive Officer, commented, “We are very pleased with SFDA’s acceptance of our application package and look forward to working with the SFDA to move the process forward towards approval.  SFDA’s approval of our application would pave the way for us to conduct global clinical trials in China and advance our ongoing Phase 2 triple-negative breast cancer trial currently underway at the University of Colorado and Indiana University.

“Our filing with SFDA represents an important milestone for us.  As a clinical-stage drug development company, competition in patient recruitment, time, and costs can be challenging when advancing clinical programs. We address this by building a value-added platform via a joint US-China drug development model that will enable us to do the trials with lower study costs and faster patient recruitment.  The data we obtain may be used to support both global drug development and China import drug registration as appropriate.”

Dr. Ren continued, “We will also pursue developing ENMD-2076 in other indications where activity has been shown, including ovarian cancer, sarcoma and liver cancer, based on our prioritized product development plan.  We believe positive results from these efforts will add value to our patients, shareholders, as well as to the company.

“In addition, we have initiated local manufacturing and pre-clinical activities of ENMD-2076 in China to target specific unmet medical needs, such as hepatocellular carcinoma, which could support a new drug trial application with SFDA.  Our local development activities demonstrate EntreMed’s commitment to develop a strong presence in the Chinese market, which has been projected to become the second largest pharmaceutical market in coming years.  We believe we are on track with our development plan and are grateful to our shareholders for their enthusiasm, patience, and long term support.”

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for cancer, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Its second compound, 2ME2, has been investigated in clinical trials in oncology patients, and was the subject of a successful IND filing for clinical use to treat RA in 2006.  Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid^® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com

Zoom (ZOOM) Announces Sale of China-Based Operations Strategy to Acquire U.S.-Based

BEIJING, Jan. 7, 2013 (GLOBE NEWSWIRE) — Zoom Technologies, Inc. (Nasdaq:ZOOM) a leading designer and manufacturer of mobile phones and consumer electronics, announced the execution of a definitive agreement pursuant to which it will sell its China-based manufacturing, sales and marketing, and R&D subsidiaries, and that the proceeds of the sale will be used for the purchase of additional U.S.-based businesses.

On December 31, 2012, Zoom Technologies, Inc. (“Zoom” or the “Company”) entered into a Share Purchase Agreement with the Beijing Zhumu Culture Communication Company, Ltd. (the “Purchaser”), a PRC company that provides services to the telecommunication industry, for the sale to the Purchaser of the Company’s China based operations including: 100% ownership of Beijing Nollec Wireless Company (“Nollec”) – the R&D subsidiary, 80% ownership of Tianjin Tongguang Group Digital Communication Company, Ltd. (“TCBD”) – the main manufacturing entity, 100% ownership of Profit Harvest Corporation, Ltd. (“Profit Harvest”) – the sales & marketing company, and 100% ownership of Celestial Digital Entertainment, Ltd. (“CDE”) – the mobile game maker. As consideration for the sale, the Purchaser shall pay the Company an aggregate of Rmb 200 million, equivalent to approximately US$32 million. The purchase price is, subject to adjustment pending an appraisal by an independent third party appraiser. As of the date of the Share Purchase Agreement, the Purchaser has deposited the full amount of RMB 200 million into an escrow account, to be released to the Company upon the final closing of the Sale, which will be held 30 days after the Company receives all the requisites corporate and regulatory approvals with respect to the Sale.

The Company’s ownership interest in SpreadZoom Technologies Co., Ltd., which owns and operates mobile phone manufacturing facilities in Tianjin and which is a joint-venture between the Company and Spreadtrum Technologies, Inc., is not part of the sale.

The final closing of the sale of the above-mentioned subsidiaries of the Company is anticipated to take place within the first quarter of 2013 with the exception of Profit Harvest which closing occurred as of December 31, 2012. In addition, the Company will, through Portables Unlimited, LLC, its U.S. based subsidiary, continue to operate the exclusive wholesale distributor business for T-Mobile products and services in the United States.

The Company intends to use the cash proceeds from the sale of the assets to acquire similar businesses in the U.S. to further expand its activities there, including but not limited to the acquisition of additional licensed retail stores that service T-Mobile USA.

Zoom’s Chairman & CEO, Mr. Leo Gu stated, “Our strategy is a simple one. We will focus our resources to capture revenues from U.S. based operations, which we started over a year ago by our acquisition of Portables Unlimited in New York. With this sale, our revenues will be predominantly generated from our U.S. operations. The selling of our China based operations doesn’t mean that we are out of touch with China because we can always contract with our former subsidiaries, when the need arises going forward. We feel that it is important to listen to the market which has not been favorable Chinese companies listed in the U.S., and we are confident that the combination of our continued relationships in China and the expansion of our U.S. activities is a positive direction for Zoom Technologies. We are actively seeking synergistical businesses to bring into Zoom and adding on more licensed retail stores of T-Mobile USA is a part of this plan.”

About Zoom Technologies, Inc.

Zoom Technologies is a holding Company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for the latest generation of mobile phones, wireless communication circuitry and related software products. Zoom Technologies’ current subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the ZOOM, LEIMONE and LONGTEL brand names. The Company’s products are both exported globally and sold domestically in People’s Republic of China. Zoom Technologies also owns a controlling interest in Portables Unlimited LLC, a cellular service and products distributor in the U.S.

The Zoom Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9665

Forward-Looking Statements

Certain statements in this press release may constitute “forward looking statements” that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events in which the outcome cannot be assured. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.

CONTACT: Investor Contact:
         Lynn Wei
         Investor Relations Coordinator
         Zoom Technologies, Inc.
         +86-10-5935-9576
         weilin@zoom.com
         www.zoom.com

Peregrine (PPHM) Update on Phase II Lung Cancer Trial Internal Review

TUSTIN, CA — (Marketwire) — 01/07/13 — Peregrine Pharmaceuticals, Inc.(NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients. The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA. The internal review included a thorough operational review of multiple third-party vendor operations at sites worldwide, testing of investigational product used in the trial, additional patient sample testing to determine drug levels and a review of immunogenicity testing results from the trial. The results of the extensive internal review indicate that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.

“Our goal in undertaking such a comprehensive review was to understand every aspect of this clinical trial,” said Jeffrey L. Masten, vice president, quality of Peregrine. “Due to the complex nature of this trial, this was an enormous effort involving multiple third-party vendors and thousands of product and patient samples obtained from three different continents. Specifically, we sought to determine the cause and the impact of any discrepancies within the trial and to verify every step within the drug product distribution process. We believe we have accomplished our goals in obtaining a more thorough understanding of the trial and we are very pleased with the outcome.”

Based on the results of the internal review, Peregrine is taking a very conservative approach toward analyzing the results from the trial which included combining the placebo and 1mg/kg arms into one treatment arm (control arm), and comparing those results to the 3mg/kg arm. This analysis indicates that the 3 mg/kg arm continues to show favorable tumor response rates, progression-free survival and overall survival (OS) over the new combined control arm. Peregrine expects to announce more detailed results from the analysis in the near term when it is completed.

“The results from this comprehensive review have provided a better understanding of the outcome of this trial. We believe that these results of our internal review and subsequent data analysis support advancing bavituximab into Phase III development for the treatment of second-line non-small cell lung cancer,” said Joseph S. Shan, vice president, clinical and regulatory affairs of Peregrine. “We are now preparing for discussions with the FDA and worldwide regulatory agencies.”

“With the results of this review in hand, we are now in the process of updating potential partners and moving the program forward,” said Steven W. King, president and chief executive officer of Peregrine. “Looking ahead, we anticipate data from seven ongoing bavituximab trials in different indications as well as results from an imaging study based on the same novel target.”

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials, including three randomized Phase II trials in front-line and second-line non-small cell lung cancer and front-line pancreatic cancer, and five investigator-sponsored trials (ISTs) in additional oncology indications. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the final OS data from the randomized, double-blind, placebo-controlled Phase IIb trial may be less compelling than the data as presently calculated thereby creating uncertainty with respect to the future development in second-line NSCLC, the risks that partnering discussions may not result in a partnering transaction or that such discussions could be hindered or delayed as a result of the existing class action lawsuits, the risk that results from the front-line NSCLC trail will not be consistent with results experienced in earlier trials and may not support advancing this indication into later stage trials. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended October 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended October 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

GlobalWise (GWIV) Enters New Channel Sales Partnership With Iron Data

COLUMBUS, OH — (Marketwire) — 01/07/13 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce the signing of a new channel sales partnership with Iron Data Solutions, Inc. (www.irondata.com).

Headquartered in Arlington, VA, Iron Data offers a comprehensive suite of solutions, called Intelligent Process Management, that assess, improve, manage and monitor challenging operational process issues for clients in the public sectors. Iron Data has more than 400 employees across 11 offices around the U.S. and the world, including Amsterdam, Toronto and Shenzhen, China.

“Iron Data represents another fantastic channel partner who can further expand our scope in both the public and private sector through their technological expertise and established relationships,” stated William “BJ” Santiago, CEO of GlobalWise. “Iron Data has been a proven leader in transforming how government agencies control dataflow and manage information. We are actively working to secure a large government client now and anticipate announcing a new contract with the organization soon. GlobalWise looks forward to working with Iron Data and anticipates many more client opportunities over the coming quarters.”

“We deeply value our government clients and relationships,” said Tom Gottleib, Vice President of Iron Data. “It was vitally important we found an ECM cloud-based provider who understood the mission critical and privacy needs within the government sector. GlobalWise has served these types of clients since their inception and has a rich and proven legacy to complement our reputation for implementing process management and business automation solutions that reduce waste, fraud and abuse.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Alderon (AXX) to Release FeasibilityStudy, Host Conference Call on Kami Iron Ore Project

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 01/04/13 — Alderon Iron Ore Corp. (TSX:ADV)(NYSE MKT:AXX) (“Alderon”) is pleased to announce that it plans to release the results of its Feasibility Study (“FS”) on the Rose Deposit of the Kamistiatusset (“Kami”) Iron Ore Property in western Labrador prior to market open on Wednesday January 9, 2013.

Following the release of the FS, Alderon will host an analyst and shareholder conference call at 8:00am EST on the same day (January 9, 2012). To participate in the call, please dial the following:

Toronto: 416-623-0333
Montreal: 514-687-4017
Vancouver: 604-681-8564
Calgary or International: 403-532-5601                                      

Toll Free North America: 1-855-353-9183                                     

Participant Pass Code: 43764#

About Alderon

Alderon is a leading iron ore development company in Canada with offices in Vancouver, Toronto, Montreal, Labrador City and St. John’s. The 100% owned Kami Project is located within Canada’s premier iron ore district and is surrounded by four producing iron ore mines. The Alderon team is comprised of skilled professionals with significant iron ore expertise to advance Kami towards production.

For more information on Alderon, please visit our website at www.alderonironore.com.

ALDERON IRON ORE CORP.

On behalf of the Board

Mark J. Morabito, Executive Chairman

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” concerning anticipated developments and events that may occur in the future. Forward looking information contained in this press release include, but are not limited to, statements with respect to the release of the results of the Feasibility Study.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking information contained in this press release is based on certain factors and assumptions regarding, among other things, the estimation of mineral reserves and resources, the realization of resource estimates, iron ore and other metal prices, the timing and amount of future exploration and development expenditures, the estimation of initial and sustaining capital requirements, the estimation of labour and operating costs, the availability of necessary financing and materials to continue to explore and develop the Kami Property (as defined herein) in the short and long-term, the progress of exploration and development activities, the receipt of necessary regulatory approvals, the completion of the environmental assessment process, the estimation of insurance coverage, and assumptions with respect to currency fluctuations, environmental risks, title disputes or claims, and other similar matters. While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined including the possibility that mining operations may not commence at the Kami Property, risks relating to variations in mineral resources, grade or recovery rates resulting from current exploration and development activities, risks relating to the ability to access rail transportation, sources of power and port facilities, risks relating to changes in iron ore prices and the worldwide demand for and supply of iron ore and related products, risks related to increased competition in the market for iron ore and related products and in the mining industry generally, risks related to current global financial conditions, uncertainties inherent in the estimation of mineral resources, access and supply risks, reliance on key personnel, operational risks inherent in the conduct of mining activities, including the risk of accidents, labour disputes, increases in capital and operating costs and the risk of delays or increased costs that might be encountered during the development process, regulatory risks, including risks relating to the acquisition of the necessary licences and permits, financing, capitalization and liquidity risks, including the risk that the financing necessary to fund the exploration and development activities at the Kami Property may not be available on satisfactory terms, or at all, risks related to disputes concerning property titles and interest, environmental risks, and the additional risks identified in the “Risk Factors” section of the Company’s Annual Information Form for the most recently completed financial year or other reports and filings applicable Canadian securities regulators. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this press release. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information.

Contacts:
Alderon Iron Ore Corp.
Montreal Office
514-281-9434
514-281-5048 (FAX)

Alderon Iron Ore Corp.
St. John’s Office
709-576-5607
709-576-7541 (FAX)

Alderon Iron Ore Corp.
Labrador City
709-944-4820
709-944-4827 (FAX)

Alderon Iron Ore Corp.
Toronto Office
416-309-2138
416-861-8165 (FAX)

Alderon Iron Ore Corp.
Vancouver Office
604-681-8030
604-681-8039 (FAX)

Alderon Iron Ore Corp.
Konstantine Tsakumis
Investor Relations
1-866-683-8030 ext. 232
info@alderonironore.com

Brower Piven Encourages Investors to Inquire About Hemispherx Biopharma (HEB) Class Action

Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the February 22, 2013 Lead Plaintiff Deadline — HEB

STEVENSON, Md., Jan. 4, 2013 (GLOBE NEWSWIRE) — Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (NYSE MKT:HEB) common stock during the period between March 19, 2012 and December 17, 2012, inclusive (the “Class Period”).

If you have suffered a net loss from investment in Hemispherx Biopharma, Inc. common stock purchased on or after March 19, 2012, and held through December 17, 2012, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than February 22, 2013 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period details concerning the safety and efficacy of Ampligen being developed for the treatment of Myalgic Encephalomylitis / Chronic Fatigue Syndrome.  According to the Complaint, following the FDA’s December 18, 2012 report which found the Company’s studies were ill-defined and invalid and showed inconsistent signals of efficacy and which identified nine potential safety concerns associated with Ampligen, the value of Hemispherx shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven
         Brower Piven, A Professional Corporation
         Stevenson, Maryland
         410/415-6616
         hoffman@browerpiven.com

Amicus (FOLD) Announces Positive Results, Phase 2 Pompe Disease

Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

CRANBURY, N.J., Jan. 4, 2013 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme^® and Lumizyme^®). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease. Based on the Study 010 results, Amicus expects to initiate a repeat-dose clinical study in the third quarter of 2013.

For people with Pompe disease, deficient GAA enzyme leads to the accumulation of glycogen in tissues affected by disease (primarily muscle). Preclinical data¹ demonstrated that AT2220 in combination with ERT enhances rhGAA enzyme activity, reduces glycogen accumulation, and potentially mitigates ERT-related immunogenicity in a mouse model of Pompe disease. In Study 010, co-administration of AT2220 to Pompe patients increased rhGAA enzyme activity and enhanced rhGAA enzyme uptake into muscle tissue compared to ERT alone.

John F. Crowley, Chairman and Chief Executive Officer stated, “Study 010 has established human proof-of-concept that AT2220-ERT co-administration increases GAA enzyme activity in muscle. We look forward to initiating our repeat-dose clinical study to investigate the effect of AT2220-ERT co-administration on ERT stability and activity, ERT-related immunogenicity, and other clinical measures. We believe that co-administration may deliver significant benefits compared to ERT alone and become an important therapy for people with Pompe disease.”

Additional details surrounding the development strategy for AT2220 in combination with ERT for Pompe disease will be provided during a live presentation and webcast at the 31^st Annual JPMorgan Healthcare Conference on January 9, 2013 at 3:00 p.m. PT.

Study 010 Results – AT2220 Co-Administered with ERT (n=23)

Study 010 investigated single ascending oral doses of AT2220 co-administered with Myozyme or Lumizyme in patients with Pompe disease. The doses of AT2220 were 50 mg (Cohort 1), 100 mg (Cohort 2), 250 mg (Cohort 3), and 600 mg (Cohort 4). Each patient received one infusion of ERT alone, and then a single oral dose of AT2220 one hour before the next ERT infusion. Highlights from all four dose cohorts of AT2220 were as follows:

Safety: Single doses of AT2220 co-administered with ERT were well-tolerated, with no drug-related adverse events reported. In addition, AT2220 was cleared from muscle to near-undetectable levels by Day 7 in all four cohorts.

Recombinant Human GAA (rhGAA) Enzyme Activity in Plasma: 24-hour plasma PK was measured during and after each infusion. Plasma rhGAA activity increased in 23 out of 23 patients (100%) following co-administration and the increases were dose-related. These data suggest that co-administration increases the amount of stabilized, properly folded, and active rhGAA enzyme available for uptake into tissue.

Enzyme Activity in Muscle: Muscle biopsies were taken to measure GAA enzyme uptake into muscle tissue, with and without AT2220. In Cohort 1, all 4 patients had muscle biopsies on Day 7. In Cohorts 2-4, muscle biopsies were taken on Day 3 for half the patients, and on Day 7 for the other half of patients.

In Cohort 1, no consistent change in GAA enzyme activity was observed at day 7. In Cohorts 2, 3, and 4 the results show that more enzyme is taken up into muscle tissue following AT2220 co-administration compared to ERT alone. The effect was most pronounced at the highest (600 mg) dose of AT2220.

At Day 3 the GAA enzyme activity in muscle following co-administration compared to ERT alone in patients with evaluable biopsies increased by the following: 25% in Cohort 2 (n=3), 7% in Cohort 3 (n=3), and 133% in Cohort 4 (n=2). At Day 7 the GAA enzyme activity in muscle was lower relative to Day 3, as expected based on the cellular half-life of the enzyme. However, following co-administration compared to ERT alone in patients with evaluable biopsies the following increases were sustained: 20% in Cohort 2 (n=3), 40% in Cohort 3 (n=2), and 20% in Cohort 4 (n=3).

Effect of AT2220 on ERT-Related Immunogenicity Measured ex vivo

By stabilizing the folded and active form of the rhGAA enzyme, AT2220 may mitigate ERT-induced immunogenicity since unfolded and aggregated proteins are generally more antigenic than properly folded proteins. Recent published studies show that approximately 40% of the administered ERT can be captured by circulating antibodies and infusion associated reactions occur in approximately 50% of Pompe patients receiving ERT infusions.² Initial ex vivo studies using T cells derived from blood from 50 healthy donors demonstrated that the addition of AT2220 may significantly reduce the immunogenicity of Myozyme and Lumizyme. The studies utilized Antitope Ltd.’s EpiScreen™ assay and are being repeated in samples from the Pompe patients in Study 010. Results from these ex vivo studies may help to guide the clinical investigation of the effects of AT2220 on ERT-related immunogenicity.

Study 010 Design

Study 010 is a Phase 2 open-label, multi-center study to evaluate the safety and PK effects of four increasing oral doses of AT2220 (50 mg, 100 mg, 250 mg, or 600 mg) co-administered with ERT (Myozyme^®/Lumizyme^®) versus ERT alone in males and females with Pompe disease. The study enrolled male and female patients who had been on a stable dose and regimen of ERT for at least three months. All patients were given a regularly scheduled ERT infusion. One hour prior to the initiation of the next ERT infusion, patients received a single oral dose of AT2220. Plasma rhGAA activity and protein levels were evaluated during each infusion. Each patient underwent muscle biopsies three or seven days after each infusion to measure tissue GAA enzyme activity with and without the chaperone, as well as to measure the level of AT2220 in the muscle. More information about Study 010 can be obtained by visiting www.clinicaltrials.gov: NCT1380743 or www.pompestudy.com.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus’ late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.

About AT2220 for Pompe Disease

AT2220 is an investigational, orally-administered pharmacological chaperone owned exclusively by Amicus. The Company has completed a Phase 2 study (Study 010) of AT2220 (duvoglustat HCl) co-administered with the ERT alglucosidase alfa (Myozyme/Lumizyme) in individuals with Pompe disease. Published preclinical data¹ suggest that AT2220 in combination with this ERT may improve rhGAA enzyme activity, reduce glycogen accumulation, and potentially mitigate ERT-related immunogenicity in patients with Pompe disease.

Pompe disease is a lysosomal storage disease characterized by progressive skeletal muscle weakness and respiratory insufficiency. It is caused by a deficiency in GAA activity, which leads to accumulation of glycogen in tissues affected by the disease (primarily muscle). Pompe disease affects an estimated 5,000 to 10,000 individuals worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease. The clinical benefit of Myozyme and Lumizyme may be limited by low stability of the recombinant enzyme at neutral pH and body temperature, modest tissue uptake, and immune responses that affect tolerability and efficacy. Immune responses in the form of antibodies to rhGAA occur in a majority of Pompe patients receiving Myozyme/Lumizyme infusions³ and may limit treatment outcomes with ERT.

1.  Khanna R, et al., The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease., PLoS ONE (2012) 7(7): e40776. doi:10.1371/journal.pone.0040776.

2.  Banati M, et al., Enzyme Replacement Therapy Induces T-cell Responses in Late-Onset Pompe Disease., Muscle Nerve. 2011 Nov;44(5):720-6.

3.  Lacana E, et al., The Role of Immune Tolerance Induction in Restoration of the Efficacy of ERT in Pompe Disease., Am J Med Genet C Semin Med Genet. 2012 160C:30-39

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to clinical development of Amicus’ candidate drug products and the timing and reporting of results from clinical trials evaluating Amicus’ candidate drug products. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition, all forward looking statements are subject to other risks detailed in our Quarterly Report on Form 10-Q for the year ended September 30, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044

         Media:
         Dan Budwick
         (973) 271-6085
         dan@purecommunicationsinc.com

Good Times Restaurants (GTIM) Announces First Quarter Sales Increase

Cardium (CXM) To Report On Initiatives At Biotech Showcase 2013 Investment Conference

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, the Company’s Chairman & CEO, will present at the Biotech Showcase 2013 Conference, being held at the Parc 55 Wyndham San Francisco Union Square Hotel, on Monday, January 7, 2013 at  2:15 p.m. (Pacific).  The presentation will be available live and by replay and can be accessed at http://www.media-server.com/m/p/xv9nyge4 or at Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The presentation will provide a corporate overview and include a review of the Company’s entrepreneurial initiatives, which include strategic partner-enabled product and platform opportunities that have been internally developed based on Cardium’s unique skill set, capabilities and technology.

Current entrepreneurial initiatives include: (1) the clinical development of Genedexa™ (previously referred to as the Excellarate™ product candidate), a DNA-based Phase 2b/3 product candidate initially for the treatment of chronic, non-healing diabetic foot ulcers and representing the first product extension from the Company’s FDA-cleared Excellagen^® technology platform; (2) LifeAgain™, a medical analytics and e-commerce platform of algorithms and medical-based social media programs that were developed by Cardium researchers to support a strategically partnered commercialization of specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases, based on the improvement of early diagnosis and new chronic treatments and curative medical therapies; and (3) plans to leverage the established infrastructure, distribution capabilities and established retail network of To Go Brands^® through internal product development, external product acquisitions and strategic partnering.

Going forward, the Company may use alternative independent private financing strategies for one or more of these internally developed initiatives.  Cardium Therapeutics will continue to focus on its primary objectives that include: (1) the strategic partnering and commercialization of the FDA-cleared Excellagen^® product and platform; and (2) the successful completion of the DNA-based Generx^® Phase 3 development program. Information is provided in an updated investor presentation now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s newly-acquired To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that any entrepreneurial initiatives, including Genedexa, Life Again, and other prospective opportunities developed within Cardium, Tissue Repair Company or To Go Brands will be successfully developed and partnered or otherwise commercialized; that the results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo^®, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen^®, Genedexa™, Excellarate™, Osteorate™, MedPodium^®, Appexium^®, Linée^®, Alena^®, Cerex^®, D-Sorb™, Neo-Energy^®, Neo-Carb Bloc^®, Neo-Chill^™, and Nutra-Apps^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.
To Go Brands^® is a trademark of To Go Brands, Inc.

SolarCity (SCTY) Announces Fiscal Year 2012 Update and Fiscal Year 2013 Guidance

SolarCity Corporation (Nasdaq:SCTY), a provider of clean, distributed energy, today announced an update on the Company’s megawatts (MW) deployed for the Fiscal Year ended December 31, 2012 and Q4 2012, and provided guidance on this metric for 2013.

“Following the completion of our IPO on December 12, 2012 and the completion of the fiscal year on December 31, the Company now has its first opportunity to provide an update on 2012 megawatt deployment and a forecast of megawatt deployment for 2013,” said SolarCity CEO Lyndon Rive.

Fiscal Year 2012 Update

• In Fiscal Year 2012, the Company deployed 156 MW, against a plan of 146 MW deployed.
  • This represents 117% growth over 72 MW deployed in 2011.
  • Q4 2012 deployments totaled 47 MW.
  • Residential deployments were 85 MW for Fiscal Year 2012 and 30 MW for Q4 2012.
  • Commercial deployments, including non-residential government deployments, were 71 MW for Fiscal Year 2012 and 17 MW for Q4 2012.

Fiscal Year 2013 Guidance

• The Company expects Fiscal Year 2013 deployments to be 250 MW.
  • The Company expects residential deployments to be 190 MW in Fiscal Year 2013.
  • The Company expects commercial deployments to be 60 MW in Fiscal Year 2013.

In the future, the Company expects to provide guidance on these and other financial and operating metrics during its quarterly earnings calls, but is making an exception to that process now as it has not had the opportunity to provide 2013 guidance.

About SolarCity

SolarCity® (NASDAQ:SCTY) provides clean energy. The company has disrupted the century-old energy industry by providing renewable electricity directly to homeowners, businesses and government organizations for less than they spend on utility bills. SolarCity gives customers control of their energy costs to protect them from rising rates. The company offers solar power, energy efficiency and electric vehicle services, and makes clean energy easy by taking care of everything from design and permitting to monitoring and maintenance. SolarCity currently serves 14 states and signs a new customer every five minutes. Visit the company online at www.solarcity.com and follow the company on Facebook & Twitter.

Forward Looking Statements

This release contains forward-looking statements including, but not limited to, statements regarding 2013 megawatt deployment, future cashflow results, plans for investment, growth and future operations, and assumptions relating to the foregoing. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward looking statements, including the effect of electric utility industry regulations, net metering and related policies, the availability and amount of rebates, tax credits and other financial incentives, the availability and amount of financing from fund investors, the retail price of utility-generated electricity or the availability of alternative energy sources, the completion of year-end accounting procedures and the year-end audit and other factors. You should read the section entitled “Risk Factors” in our registration statement on Form S-1, which has been filed with the Securities and Exchange Commission, which identifies certain of these and additional risks and uncertainties. We do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Intellicheck (IDN) to Present at the Sidoti Micro-Cap Conference in NYC on Jan 7

Intellicheck Mobilisa, Inc. (NYSE MKT: IDN) (“the Company”), a global leader in access control and wireless security systems, announced that its Chief Financial Officer, Bill White, will be presenting at Sidoti & Company’s Annual Micro-Cap Conference to be held at the Grand Hyatt New York Hotel in New York City on Monday, January 7, 2013. He is scheduled to present from 8:40 am to 9:15 am ET in the Carnegie Hall Room.

About Sidoti & Company, LLC

Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable companies at a sub-$3 billion market cap. For more information or to register for the conference, please visit http://microcap.sidoti.com.

About Intellicheck Mobilisa

Intellicheck Mobilisa is a leading technology company providing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. Products include the Fugitive Finder system, an advanced ID card access control product currently protecting military bases and secure federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs, designed to improve the Customer Experience for the financial, hospitality and retail sectors; and Aegeus, a wireless security buoy system for the government, military and oil industry. For more information on Intellicheck Mobilisa, please visit www.icmobil.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, words such as “will,” “believe,” “expect,” “anticipate,” “encouraged,” and similar expressions, as they relate to the company or its management, as well as assumptions made by and information currently available to the company’s management identify forward-looking statements. Actual results may differ materially from the information presented here. Additional information concerning forward-looking statements is contained under the heading of risk factors listed from time to time in the company’s filings with the SEC. We do not assume any obligation to update the forward-looking information.

Zumiez Inc. (ZUMZ) Reports December 2012 Sales Results

LYNNWOOD, WA — (Marketwire) — 01/03/13 — Zumiez Inc. (NASDAQ: ZUMZ), a leading specialty retailer of action sports related apparel, footwear, equipment and accessories, today announced that total net sales for the five-week period ended December 29, 2012 increased 15.0% to $120.3 million, compared to $104.6 million for the five-week period ended December 31, 2011. The Company’s comparable store sales decreased 1.0% for the five-week period versus a comparable store sales increase of 10.0% in the year ago period.

To hear the Zumiez prerecorded December sales message, please dial (201) 689-8483 or (877) 523-5612, followed by the passcode # 986439 (ZUMIEZ).

About Zumiez Inc.

Zumiez is a leading multi-channel specialty retailer of action sports related apparel, footwear, equipment and accessories, focusing on skateboarding, snowboarding, surfing, motocross and BMX for young men and women. As of December 29, 2012 we operated 502 stores, 474 in the United States, 20 in Canada, and 8 in Europe. In the United States and Canada we operate under the name Zumiez and in Europe we operate under the name Blue Tomato. Additionally, we operate ecommerce web sites under www.zumiez.com and www.blue-tomato.com.

Company Contact:
Brian Leith
Director of Finance &
Investor Relations
Zumiez Inc.
(425) 551-1500, ext. 1610

Investor Contact:
ICR
Brendon Frey

Zalicus (ZLCS) Initiates the Second of Two Phase 2a Studies with Z160

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated the second of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type (Cav2.2) calcium channel blocker for the potential treatment of chronic neuropathic pain. The Company also provided an overview of 2012 accomplishments.

Z160 is designed to selectively target neuronal pain signaling by modulating neurons that are undergoing high-frequency firing. Z160 has demonstrated efficacy in several animal models of neuropathic pain, and clinical trials in over 200 subjects have established Z160 as a safe and well tolerated drug candidate.

The second Phase 2a study with Z160 is enrolling subjects with Postherpetic Neuralgia (PHN), a chronic neuropathic pain state resulting from an outbreak of the herpes zoster virus, otherwise known as shingles. Due to this prolonged neuropathic pain, PHN is an industry-accepted standard condition for establishing clinical proof-of-concept for pharmaceutical product candidates seeking to address neuropathic pain. The 6-week, double-blind, multi-center, randomized, placebo-controlled study is expected to enroll approximately 140 subjects and will be conducted in approximately 35 centers throughout the United States. The primary objective of the trial is to evaluate the efficacy of Z160 compared to placebo in reducing pain in subjects with PHN as measured by the change in average weekly pain score from baseline to week 6 of treatment based on a daily 11-point Pain Intensity Numeral Rating Scale (PI-NRS).

“Postherpetic Neuralgia is an important medical condition for evaluating the activity of Z160 for three important reasons. First, it is a well-recognized standard for establishing clinical proof of concept in neuropathic pain; second, with a prevalence of less than 200,000 patients in the U.S., it has the potential for orphan drug status and could be a feasible first indication to pursue from a commercial perspective; and third, significant unmet medical need exists for novel, targeted and more efficacious chronic neuropathic pain therapies with improved safety and tolerability profiles such as Z160,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus.

The first Phase 2a clinical study with Z160, which began enrolling patients in August of 2012, is evaluating the activity of Z160 in subjects with pain associated with Lumbosacral Radiculopathy, a chronic neuropathic pain condition resulting from the compression or irritation of the nerve roots exiting the lumbar region of the spine.

2012 Accomplishments:

• Z160. Advanced Z160, a first-in-class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker into two Phase 2a clinical trials for neuropathic pain including lumbosacral radiculopathy (LSR) which began in the third quarter of 2012 and postherpetic neuralgia which began in the fourth quarter of 2012. Top line data from both studies are expected to be available late in the second half of 2013.
• Z944. Completed Phase 1 single and multiple ascending dose clinical studies with Z944 and are consulting with regulatory authorities on the clinical path forward. Z944 is a novel, oral, T-type calcium channel blocker which has demonstrated efficacy in a number of preclinical inflammatory pain models and other disease models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling.
• Sodium Channel Blockers. Working to discover novel, oral, selective, state-dependent sodium channel blockers. Sodium channel blockers are a promising target linked to chronic pain.
• Exalgo. A 32mg dosage strength of Exalgo was approved by the FDA in August 2012. We have received over $7.9 million in royalty revenue on Exalgo sales through the quarter ended September 30, 2012.
• Prednisporin. Sanofi announced its intention to continue Prednisporin development under a third party sublicense. Future potential milestone payments and royalties to Zalicus will remain in place.
• cHTS. Our combination drug discovery research services business on track to generate approximately $7.0 million of revenue in 2012.

“During 2012, we made a number of advances with our novel ion channel programs, including advancing our novel formulation of Z160 into Phase 2 clinical development and advancing Z944 into the clinic,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “We plan to build on this success in 2013 by generating proof-of-concept data for Z160 in multiple indications and seeking to advance the development of our other ion channel programs.”

About Zalicus

Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain such as Z160 and Z944 and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its product candidates, their potential and the plans for their clinical and preclinical development, the Zalicus selective Ion channel modulation technology and related preclinical product candidates, Zalicus’ combination drug discovery technology, cHTS, and its financial condition, results of operations, and other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the sale and marketing of Exalgo by Covidien, risks related to the development and regulatory approval of Zalicus’ product candidates, including risks relating to formulation and clinical development of Z160 and Z944, the unproven nature of the Zalicus drug discovery technologies, the ability of the Company or its collaboration partners to initiate and successfully complete clinical trials of its product candidates, the Company’s ability to obtain additional financing or funding for its research and development, and those other risks that can be found in the “Risk Factors” section of Zalicus’ annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

Cardium (CXM) Announces Sales and Distribution Agreement With Academy Medical

Cardium Announces Sales and Distribution Agreement With Academy Medical to Promote Excellagen Clinical Adoption by U.S. Government Medical Providers

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced a distribution agreement with Academy Medical, LLC to market, sell and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals.  Excellagen is FDA-cleared, to support advanced wound care in a broad range of dermal wounds.  Academy Medical’s initial focus will be to provide education and training on the use of Excellagen in the treatment of traumatic wounds, non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery and to support distribution within its growing customer base of over 35 VA and military hospitals within the U.S.

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The VA operates the nation’s largest integrated healthcare system.  With a healthcare budget of more than $50 billion, VA expects to have provided care to over 6.0 million patients during over 900,000 inpatient hospital admissions and nearly 80 million outpatient visits during 2012.  VA’s healthcare network includes 152 major medical centers and more than 800 community-based outpatient clinics.

“As the U.S. healthcare market continues to expand due to the aging population and with the implementation of the Affordable Care Act, simpler-use and more cost-effective medical products like Excellagen have an opportunity to expand and grow within outcomes-oriented healthcare settings,” stated Christopher J. Reinhard, Chairman and CEO of Cardium.  “Our agreement with Academy Medical expands Cardium’s tactical access and distribution capabilities for Excellagen as we advance forward with our planned U.S. strategic partnering activities.  We are in discussions with potential strategic partners to establish representation, marketing and sales, or co-promotional arrangements along four U.S. vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government medical service providers; and (4) dermatology.”

Consistent with Cardium’s long-term business strategy, the Company does not plan to establish an internal sales force for Excellagen.  This commercialization strategy is similar to other companies in the advanced wound care space.  For example, GraftJacket^® products developed by Wright Medical are now being marketed and sold by Kinetic Concepts Inc.; TEI Biosciences’ products are being sold by Boston Scientific, Medtronic and Stryker; and Cook Medical’s Oasis^® products are currently being marketed and sold by Healthpoint Biotherapeutics.

About Academy Medical, LLC

Academy Medical is a certified Veteran Owned Small Business specializing in the distribution of medical products to Department of Veterans Affairs and Department of Defense hospitals and community-based outpatient clinics. As the largest distributor of biologics on the Federal Supply Schedule, Academy Medical supports veterans, healthcare providers, and governmental purchasing officials with cutting edge products backed by the company’s professional expertise. Additional information is available at www.academymedical.net.

About Excellagen

Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen gel that functions as an acellular biological modulator designed to accelerate the growth of granulation tissue and to activate the wound healing process.  Excellagen is FDA-cleared for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds, and is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique high-molecular weight fibrillar Type I bovine collagen gel formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and its viscosity-optimized gel formulation is designed for application at only one-week intervals.  Already-established standard CPT^® procedure reimbursement codes may apply when Excellagen is used with surgical debridement procedures.  Cardium is also advancing forward with the reimbursement process for Excellagen with Medicare & Medicaid Services (CMS) and private insurance providers.

There have been important, positive findings reported by physicians using Excellagen as part of our initial physician sampling, patient outreach and market “seeding” programs.  As case studies are being conducted, a number of physicians have reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium’s Matrix clinical study), as well as pressure ulcers, venous ulcers, and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use, and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional information regarding the diverse potential uses of Excellagen and support its medical utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s newly-acquired To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that this or other distribution agreements will effectively expand access or lead to increased adoption by medical providers; that Academy Medical or other distributors will effectively provide education and training on the use of Excellagen or that it will be useful and used in non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery; that potential strategic partnerships will be successfully established; that results or trends observed in a clinical study or follow-on case studies will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo^®, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen^®, Excellarate™, Osteorate™, MedPodium^®, Appexium^®, Linée^®, Alena^®, Cerex^®, D-Sorb™, Neo-Energy^®, Neo-Carb Bloc^®, Neo-Chill^™, and Nutra-Apps^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company. To Go Brands^® is a trademark of To Go Brands, Inc.

Other trademarks belong to their respective owners.

Longwei (LPH) Raises FY Guidance with Increased Revenue Contribution from Huajie Facility

Company expects fiscal 2013 revenue to increase 30.7% to $667.3 million, with the new Huajie facility to contribute $121.0 million

TAIYUAN CITY, China, Jan. 2, 2013 /PRNewswire/ — Longwei Petroleum Investment Holding Ltd. (NYSE MKT: LPH) (“Longwei” or the “Company”), an energy company engaged in the storage and distribution of finished petroleum products in the People’s Republic of China (“PRC”), today announced that it has raised its full-year guidance for the fiscal year ending June 30, 2013 (“FY13”).

Longwei now forecasts FY13 revenue to increase 30.7% year-over-year to $667.3 million, versus prior forecasts of $646.3 million.  Longwei also projects net income, adjusted for the warrant derivative liability, to grow approximately 23.0% year-over-year to $80.1 million, versus the prior forecast of $77.6 million.  The growth is primarily driven by the better-than-expected ramp-up of the new Huajie facility.  Longwei now expects revenue contribution from the Huajie facility of $121.0 million in FY13, up 21.0% from the prior forecast of $100.0 million.  The guidance does not account for any potential external financing for inventory, which could accelerate growth.

“The Huajie facility has captured significant market share in its region during its first three months of operations, leading to better-than-expected throughput.  This, combined with continued organic growth of the Taiyuan and Gujiao facilities, positions us well for strong growth in FY13,” said Cai Yongjun, Chairman and Chief Executive Officer of Longwei.  “We expect strong quarterly top-line and bottom-line results for the period ended December 31, 2012.”

With the addition of the Huajie facility, the Company’s total storage capacity has increased to 220,000 metric tons (“mt”).  Longwei’s storage capacity is reported in metric tons based on the mass or weight of the product converted to volume storage based on the density of the product stored in its tanks, which consists of both above and below ground storage.  The volume storage capacity measurement is calculated in accordance with industry standards.  The tank inventory has been continuously audited under U.S. GAAP procedures by a U.S.-based, PCAOB-registered public accounting firm for the past six years.

The U.S. Department of Energy has developed an online calculator under its U.S. Energy Information Administration website for the conversion of metric tons to U.S. gallons: http://www.eia.gov/kids/energy.cfm?page=about_energy_conversion_calculator-basics#mogascalc.

For the two months ended November 30, 2012, Longwei reported its revenue from product sales increased 35.0% to $107.5 million, compared to $79.6 million for the two months ended November 30, 2011.  Longwei’s product sales volume increased 26.1% for this two-month period year-over-year to 86,128mt, compared to 68,310mt for the two-month period ended November 30, 2011.  The increase in revenues was primarily attributable to the increase in the average sales price of petroleum between the periods and the volume growth of the new Huajie facility.

Longwei recently reported revenues of US $133.4 million and non-GAAP net income of $18.3 million or $0.18 per share, adjusted for the non-cash warrant derivative liability charge, for the first fiscal quarter ended September 30, 2012.  The Company’s product sales volume increased 17.8% year-over-year to 110,587mt during the quarter.  As of September 30, 2012, the Company reported total assets of US $360.0 million and book value per share of $3.47.  The Company closed on the Huajie asset purchase on September 26, 2012.

The Company’s PRC wholly-owned operating subsidiary, Taiyuan Longwei Economy & Trading Co., was one of 15 companies in Taiyuan City and one of only 140 companies in Shanxi Province recognized on February 15, 2012 as a “Provincial Honorable and Credible Enterprise” for 2010.  The Company received the award from the Shanxi Administration for Industry and Commerce based on Longwei’s reputation as a company that honors its contractual obligations and maintains its credibility with customers.  “We have worked hard to build a good reputation for the Company over our 17-year operating history.  We believe our performance has earned us the trust of our customers and our shareholders, and we will vigorously defend our reputation,” stated Mr. Cai.

“China’s GDP growth next year will exceed 8%,” predicted Lu Zhongyuan, deputy director of the Development Research Center under the State Council, or China’s Cabinet.  “There is no doubt China’s economy will grow by more than 8% percent in 2013 and the government should focus more on promoting sustainable growth and containing imported inflation.  The economy has bottomed out since June of the year, buoyed by economic restructuring, innovation incentive and the market’s self-stabilizing forces,” Lu said.  He added, “This momentum will continue to drive up growth in the year ahead.” China Daily (December 30, 2012).

About Longwei Petroleum Investment Holding Limited

Longwei Petroleum Investment Holding Limited is an energy company engaged in the storage and distribution of finished petroleum products in the People’s Republic of China. The Company’s oil and gas operations consist of transporting, storing and selling finished petroleum products, entirely in the PRC. The Company’s headquarters are located in Taiyuan City, Shanxi Province. The Company has a storage capacity for its products of 220,000 metric tons located at three storage facilities within Shanxi: Taiyuan, Gujiao and Huajie, which have an individual storage capacity of approximately 50,000 metric tons (“mt”), 70,000mt, and 100,000mt, respectively.  The Company has the necessary licenses to operate and sell petroleum products not only in Shanxi, but throughout the entire PRC. The Company’s storage tanks have the largest storage capacity of any non-government operated entity in Shanxi.

The Company seeks to earn profits by selling its products at competitive prices with timely delivery to transportation companies, coal mining operations, power supply customers, large-scale gas stations and small, independent gas stations. The Company also earns revenue from agency fees by acting as a purchasing agent for other intermediaries in Shanxi, and through limited sales of diesel and gasoline at two retail gas stations, each located at the Company’s Taiyuan and Gujiao facilities. The Company seeks to continue to expand its customer base and distribution platform through the utilization of its large storage capacity, which allows the Company the flexibility to take advantage of pricing, supply and demand fluctuations in the marketplace.

Longwei was recently named to the Forbes list of “Asia’s 200 Best Under a Billion” from a universe of 15,000 companies.  Forbes ranked the companies based on sales growth, earnings growth and return on equity in the past 12 months and over three years.  As was reported, Longwei’s three-year track record is 45% sales growth, 28% earnings per share growth and 28% return on equity.  The Forbes article can be found at: http://www.forbes.com/sites/christinasettimi/2012/07/25/asias-200-best-under-a-billion.

For further information on Longwei, please visit http://www.longweipetroleum.com. You may register to receive the Company’s future press releases on the website under ‘Email Alert.’

Forward-Looking Statements

Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about Longwei’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Longwei’s operations are conducted in the PRC and, accordingly, are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political and social conditions in the PRC and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation. Other potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain and successfully complete projects, and changes in products and competition. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the Securities and Exchange Commission.

Contact:

At the Company:
Michael Toups, Chief Financial Officer
Tel: U.S. Office +1-727-641-1357
Email: mtoups@longweipetroleum.com
Web: http://www.longweipetroleum.com

Investor Relations:
Mike Bowdoin
RedChip Companies, Inc.
Tel: +1-800-733-2447, ext. 110
Email: mike@redchip.com
Web: http://www.redchip.com

Tina Xiao
Weitian Group LLC
Tel: +1-917-609-0333
Email: tina.xiao@weitian-ir.com
Web: http://www.weitian-ir.com

TransAtlantic Petroleum (TAT) Announces 2013 Capital Expenditure Budget

TransAtlantic Petroleum Announces 2013 Capital Expenditure Budget and Production Guidance, Provides Operations Update, and Announces Organizational Enhancements

HAMILTON, Bermuda, Jan. 2, 2013 (GLOBE NEWSWIRE) — TransAtlantic Petroleum Ltd. (TSX:TNP) (NYSE-AMEX:TAT) (the “Company” or “TransAtlantic”) announces the Company’s 2013 capital budget and production guidance, as approved by its Board of Directors, provides an operations update, and announces enhancements to the Company’s organizational structure.

2013 Capital Expenditure Budget

TransAtlantic’s Board of Directors has approved a capital expenditure budget for the twelve months ending December 31, 2013 of $131 million net to the Company. The budgeted spending includes $101 million of drilling and completion expense, $19 million of seismic and $11 million of infrastructure and other.

Approximately 32% of the Company’s spending is expected to be directed to the Thrace Basin, 40% toward activity on the Molla licenses, 19% at Selmo field, and 9% on exploration and other drilling.

Actual expenditures are likely to deviate from this initial plan according to drilling results, commodity prices, cash flow and capital availability (including the consummation of one or more joint ventures). The Company expects cash flow, available credit, and cash on hand will be sufficient to fund this spending program. TransAtlantic continues to work on forming a joint venture on several of the Company’s licenses. The successful consummation of a joint venture may also provide cash for planned activities and necessitate increased drilling activity.

2013 Production Guidance

TransAtlantic currently expects production during 2013, excluding any impact from exploration drilling, to total 1.8 million to 2.1 million barrels of oil equivalent (“boe”) or an average production rate of between 5,000 and 5,700 boe per day. Crude oil is expected to account for approximately 60% of production volumes.

Regional CapEx Detail and Operations Update

Molla Area

Production from the Goksu-3H has continued at an encouraging rate, averaging 425 bbls of oil per day over its first 30 days of production, 412 bbls of oil per day over its first 60 days of production, and 477 bbls of oil per day over a recent seven day period. To further evaluate the play concept, during 2013 TransAtlantic plans to target the Mardin formation with six horizontal and one vertical wells in the Molla licenses (100% working interest).

The Company is pleased to announce that TransAtlantic’s first Bedinan test in the Molla licenses, the Bahar-1 exploration well, was successfully fracture stimulated on December 2, 2012. Sales volumes from the Bahar-1 started at a daily rate of 576 bbls of oil on December 5, 2012 and averaged 375 bbls of oil per day over the subsequent 20 days. In addition to the Bedinan oil flow test, the Hazro formation in Bahar-1 is also being tested. The Hazro exhibited oil and gas shows on the mud logs while drilling which was then corroborated by open hole log analysis and early test results are indicating productivity of approximately 150 bbls of oil per day. After the Hazro test, the Company will determine the appropriate production configuration to resume sales from the well.

In light of the Bahar-1 results, the Company plans to drill three wells targeting the Dadaş shale and/or Bedinan sandstone during 2013. TransAtlantic has recently spud the Bahar-2 exploration well, which will be drilled as a horizontal well in the Bedinan sandstone and is expected to be completed with a multi-stage frac.

TransAtlantic has allocated $15 million for seismic activities and infrastructure in the Molla area in order to appraise both the Mardin and Bedinan discoveries.

Selmo Field

As a result of advanced modeling based on reinterpreted 3D seismic and well control, the Company believes that horizontal drilling can be of large benefit to Selmo’s development. TransAtlantic’s budget therefore includes plans to drill five horizontal and one deep vertical test wells in Selmo field during 2013. The Company also expects to fracture stimulate seven existing Selmo wells during the year.

Thrace Area

During 2013 TransAtlantic plans to drill 17 wells in the Tekirdag Field area development program (41.5% working interest), eight wells testing the Hayrabolu structure area, and 11 wells in other licenses. Additionally, TransAtlantic has allocated $4 million for seismic activities and infrastructure.

Exploration Activity

During 2013 TransAtlantic plans to drill an appraisal well at Gaziantep and resume activity in Bulgaria. In the Gaziantep area, completion activity on the Alibey-1H exploration well (62.5% working interest) began in early December. Production during swabbing operations has indicated initial productivity of approximately 150 bbls of oil per day from the first stage of perforations. TransAtlantic and its partners have elected to temporarily suspend activity on the well as winter weather conditions have impeded equipment and personnel movement. The remaining prospective intervals will be completed and the well equipped for production when weather and completion tools dictate. The Company plans to drill a second well in its Gaziantep licenses to appraise the discovery and successful horizontal well test at the Alibey-1H well.

TransAtlantic is currently drilling below 9,300 feet at the Durokoy-1 well on the Idil license. The Konak-1 well on the Gurun license in central Turkey did not encounter economic levels of hydrocarbons.

Organizational Enhancements

As a result of the Company’s successful initial results in several new plays in Southeastern Turkey, and continued activity in the Thrace Basin, TransAtlantic has advanced an ongoing process to increase internal exposure to resource development practices among management and evaluation personnel. As part of this strategy, TransAtlantic is evolving toward a hub-and-spoke structure, with a strong technical team based in Dallas, Texas and regional outposts staffed predominately with local experts and asset-focused, execution-minded, operating teams who rotate frequently to North America to facilitate exposure to resource play concepts and related technology.

N. Malone Mitchell, 3^rd, TransAtlantic’s Chairman and Chief Executive Officer stated, “I am encouraged by our recent successful activity in Southeastern Turkey. We are continuing to evolve our internal structure to most appropriately develop the resources we have identified. We have a good team in place to advance our 2013 strategy, and we will continue to bolster our team with targeted hires with skills appropriate for resource development. With some successful execution of development wells with horizontal multi-completions, I believe 2013 may prove to be an impactful year for TransAtlantic.”

In facilitating this strategy, TransAtlantic’s Board of Directors has appointed Ian Delahunty to the role of President. Mr. Delahunty joined TransAtlantic in 2008 and has worked with the Company’s operations in Turkey, Romania and Morocco and has recently served as Vice President, Business Development and as Vice President, Engineering overseeing completions and workovers. Prior to working with TransAtlantic, Mr. Delahunty worked as a Senior Engineer with Schlumberger in Vietnam and the United States and as a Completions Engineer with Oxy in the United States. Mr. Delahunty will oversee all business and operational aspects of the Company and its subsidiaries and will continue leading TransAtlantic’s Business Development efforts.

Justin R. Davis has been named Vice President, Engineering and will manage production operations. Mr. Davis’ background includes significant tight reservoir experience, including previous roles serving as Operations Manager for Riata Energy’s Piceance Basin project in Colorado and stimulation design and engineering for SandRidge Energy’s West Texas assets. Mr. Davis was also previously employed in various management positions with Viking International, TransAtlantic’s former oilfield services subsidiary. In his new role Mr. Davis is responsible for completions and production engineering, and operations.

The Company has recently hired Mitchell R. Whatley to serve as Drilling Manager. Mr. Whatley is expected to start with TransAtlantic in mid-January 2013 after serving the past two years with Pioneer Natural Resources with a particular emphasis on the Eagle Ford shale. Mr. Whatley also served two years with EnCana Oil and Gas in roles targeting the Deep Bossier and the Haynesville shale plays.

Mr. Mitchell and Mustafa Yavuz will continue in their existing roles as Chairman and Chief Executive Officer and Chief Operating Officer, respectively.

Ian Delahunty, TransAtlantic’s President, stated, “As a result of the discovery of the Goksu field, the successful horizontal well test at Goksu-3H, the discovery and successful application of fracture stimulation at Bahar-1, the horizontal well discovery at Alibey-1H, and the ongoing activities in the Thrace basin, TransAtlantic has identified key organizational elements essential to advancing resource development expertise. A major part of our 2013 strategy will be to promote our technical leadership and asset team based structure.”

About TransAtlantic

TransAtlantic Petroleum Ltd. is an international energy company engaged in the acquisition, development, exploration and production of oil and natural gas. The Company holds interests in developed and undeveloped oil and natural gas properties in Turkey, Bulgaria and Romania.

The TransAtlantic Petroleum Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12745

(NO STOCK EXCHANGE, SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE INFORMATION CONTAINED HEREIN.)

Forward-Looking Statements

This news release contains statements regarding TransAtlantic’s capital spending plans for the twelve months ending December 31, 2013, oil and natural gas production expectations during the twelve months ending December 31, 2013, planned drilling of vertical and horizontal wells, planned seismic and infrastructure construction, expected start date of Mitchell R. Whatley as Drilling Manager, and other expectations, plans, goals, objectives, assumptions or information about future events, conditions, results of operations or performance that may constitute forward-looking statements or information under applicable securities legislation. Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect. In addition to other assumptions identified in this news release, assumptions have been made regarding, among other things, the ability of the Company to continue to develop and exploit attractive foreign initiatives.

Although the Company believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties include but are not limited to market prices for natural gas, natural gas liquids and oil products; estimates of reserves and economic assumptions; the ability to produce and transport natural gas, natural gas liquids and oil; the results of exploration and development drilling and related activities; economic conditions in the countries and provinces in which we carry on business, especially economic slowdowns; actions by governmental authorities, receipt of required approvals, increases in taxes, legislative and regulatory initiatives relating to fracture stimulation activities, changes in environmental and other regulations, and renegotiations of contracts; political uncertainty, including actions by insurgent groups or other conflict; the negotiation and closing of material contracts; shortages of drilling rigs, equipment or oilfield services.

The forward-looking statements or information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Note on boe

Barrels of oil equivalent, or boe, is derived by the Company by converting natural gas to oil in the ratio of six thousand cubic feet (“Mcf”) of natural gas to one bbl of oil. A boe conversion ratio of 6 Mcf to 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Boe may be misleading, particularly if used in isolation.

CONTACT: Chad Potter, VP, Financial and Investor Relations
         (214) 220-4323
         http://www.transatlanticpetroleum.com
         16803 Dallas Parkway
         Suite 200
         Addison, Texas 75001

ModusLink (MLNK) Receives NASDAQ Extension

ModusLink Global Solutions^™, Inc. (NASDAQ: MLNK) today announced that the NASDAQ Hearings Panel has granted the Company’s request to extend the stay of suspension of trading of the Company’s common stock pending completion of the hearing process and a final determination regarding continued listing. The Company received the extension by a letter received on December 31, 2012.

The Company is working to complete its previously announced process to restate financial results for certain prior periods and become current in its periodic report filings with the Securities and Exchange Commission. As disclosed on December 13, 2012, the Company received a letter from NASDAQ advising that because the Company remains noncompliant with the filing requirements for continued listing, the Company’s common stock is subject to suspension under NASDAQ Listing Rule 5250(c)(1). The Company exercised its right to appeal this determination and a hearing before NASDAQ’s Hearings Panel was granted by NASDAQ, and has been scheduled for January 31, 2013. The request for the hearing triggered a stay of the suspension for 15 days and the latest action by the NASDAQ Hearings Panel extends that stay until the hearing is held and a final determination is made. The Company will provide an update regarding its continued listing status after its hearing is conducted before the NASDAQ Hearings Panel and once a decision on the matter has been reached.

About ModusLink Global Solutions

ModusLink Global Solutions Inc. (NASDAQ: MLNK) executes comprehensive supply chain and logistics services that improve clients’ revenue, cost, sustainability and customer experience objectives. ModusLink is a trusted and integrated provider to the world’s leading companies in consumer electronics, communications, computing, medical devices, software, luxury goods and retail. The Company’s operating infrastructure annually supports more than $80 billion of its clients’ revenue and manages approximately 470 million product shipments through more than 30 sites in 15 countries across North America, Europe, and the Asia/Pacific region. For details on ModusLink’s flexible and scalable solutions visit www.moduslink.com and www.valueunchained.com, the blog for supply chain professionals.

ModusLink Global Solutions is a registered trademark of ModusLink Global Solutions, Inc. All other company names and products are trademarks or registered trademarks of their respective companies.

Forward Looking Information

Statements in this press release that are not historical facts may be deemed to be “forward-looking statements,” including those statements regarding: the Company’s progress toward completing the restatement process; the expected date for the NASDAQ hearing and the duration of the stay. Actual and anticipated future results may vary materially due to certain risks and uncertainties, including, without limitation: unanticipated accounting issues or audit issues regarding the financial data for the periods to be restated or adjusted; the inability of the Company or its independent registered public accounting firm to confirm relevant information or data; unanticipated issues that prevent or delay the Company’s independent registered public accounting firm from concluding the audit or that require additional efforts, procedures or review; the Company’s inability to design or improve internal controls to address identified issues; there can be no assurance that the Company will be successful in its appeal, receive a further extension from NASDAQ and remain listed on NASDAQ; there can be no assurance the Company will complete its restatement and become current in its regulatory filings by any future extension date approved by NASDAQ; the impact upon operations of legal compliance matters or internal controls review, improvement and remediation, including the detection of wrongdoing, improper activities or circumvention of internal controls; difficulties in controlling expenses, including costs of legal compliance matters or internal controls review, improvement and remediation; global economic conditions, especially in the technology sector, which are uncertain and subject to volatility; demand for our clients’ products, which may decline or may not achieve the levels anticipated by our clients; strain on managerial and operational resources as they try to oversee the expanded operations; failure to realize the expected benefits of restructuring and cost cutting actions; failure to expand operations in accordance with its business strategy; difficulty achieving and sustaining operating profitability if the Company’s cash balances are not sufficient to allow the Company to meet all of its business and investment goals; difficulties integrating technologies, operations and personnel in accordance with its business strategy; the Company derives a significant portion of its revenue from a small number of clients, and therefore the loss of any of those clients could significantly damage the Company’s financial condition and results of operations; the Company frequently sells to its supply chain management clients on a purchase order basis rather than pursuant to contracts with minimum purchase requirements, and therefore its sales and the amount of projected revenue that is actually realized are subject to demand variability; the Company’s pipeline of sales opportunities represents potential sales transactions and estimated annual revenue therefrom and there can be no assurance that such sales efforts will be successful or that the potential revenue will be realized; risks inherent with conducting international operations; increased competition and technological changes in the markets in which the Company competes; and the potential outcome and impact of the Company’s ongoing review of strategic alternatives. Further, there can be no assurance that the Company’s review of strategic alternatives will lead to any transaction, result in increased value to its stockholders or the realization of long-term value by stockholders.

Radiant (RLGT) Awarded More Than $650,000 and Injunctive Relief in DBA Arbitration

BELLEVUE, Wash., Jan. 2, 2013 /PRNewswire/ — Radiant Logistics, Inc. (NYSE MKT: RLGT), a domestic and international logistics services company, today announced it was awarded more than $650,000 in damages from the former shareholders of DBA Distribution Services, Inc., a company it purchased in March 2011.  In the Award of Arbitration, the arbitrator found that the DBA Shareholders breached certain representations and warranties and awarded Radiant Logistics, Inc. $654,052 for such breaches.  In addition, the arbitrator found that Paul Pollara breached his noncompetition obligation to Radiant and enjoined Mr. Pollara from engaging in any activity in contravention of his obligations of noncompetition and nonsolicitation, including activities that relate to Santini Productions and his spouse, Bretta Santini Pollara until December 29, 2014.   Finally, the arbitrator ordered Paul Pollara to pay Radiant more than $21,000, the amount of salary he received while employed by DBA and concurrently violating his noncompetition and nonsolicitation obligations.  The Award also provided that the former DBA Shareholders and Mr. Pollara must pay to Radiant the administrative fees, compensation and expenses of the arbitrator associated with the arbitration.

“The Award of Arbitration was welcomed progress in the dispute with the former DBA Shareholders,” said Bohn Crain, Founder and CEO. “The arbitration effectively awarded damages of $650,000 for claims other than the breaches of Paul Pollara under his employment agreement with our wholly owned subsidiary DBA Distribution Services, Inc. and claims in a related matter before the California Superior Court against Bretta Pollara and Oceanair, Inc.  The $650,000 award will be taken as an off-set against amounts otherwise due the former DBA Shareholders and recognized as a gain, net of associated legal costs, for the quarter ended December 31, 2012.”

Mr. Crain continued: “While we are committed to vigorously protecting our interests in situations like these, it is important to draw a distinction between the bad acts of a few individuals and the solid contributions being made by members of the DBA network across the country. We are very proud to have DBA as part of the Radiant family and although this dispute has been a distraction, it has not prevented us from progressing our growth strategy. In this regard, we look forward to providing additional updates on our integration efforts in Los Angeles and other positive network developments in the near future.”

About Radiant Logistics: (NYSE MKT: RLGT)
Radiant Logistics (www.RadiantDelivers.com) is a non-asset based transportation and logistics company providing domestic and international freight forwarding and fulfillment services through a network of company-owned and exclusive agent offices across North America.  The company operates under the Radiant, Airgroup, Adcom, and DBA brands servicing a diversified account base including manufacturers, distributors and retailers using a network of independent carriers and international agents positioned strategically around the world.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from that projected or suggested is contained in the Company’s filings with the Securities and Exchange Commission (“SEC”), copies of which are available from the SEC or may be obtained upon request from the Company.

BioCryst (BCRX) to Present at J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst is scheduled to present and provide a corporate summary and update regarding the Company at the 31^st annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2012 at 10:30 a.m. Pacific Time.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has several early-stage programs: BCX4161 and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema, BCX4430, a broad spectrum antiviral for hemorrhagic fevers, and BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C. For more information, please visit the Company’s website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

Walt Disney and Charter (CHTR) Announce New Distribution Agreement

Charter Communications and The Walt Disney Company (NYSE: DIS) today announced a comprehensive long-term distribution agreement to deliver Disney’s robust lineup of top quality sports, news and entertainment content to Charter TV customers across televisions, computers, smartphones, tablets, gaming consoles and internet-enabled televisions. The renewal agreement supports the companies’ mutual goal to deliver the best video content to customers across multiple platforms. Launch of content across these new distribution platforms is planned to begin in the first half of 2013.

As part of the new multi-year deal, The Longhorn Network will launch in Texas, Louisiana and Virginia systems by football season next year. Charter and The Walt Disney Company will also introduce several new services, including the full suite of authenticated WATCH products, ESPN Goal Line, ESPN Buzzer Beater, as well as the upcoming ABC News/Univision Joint Venture, a 24/7 news, information and lifestyle multi-platform network for English-dominant and bilingual Hispanics, the youngest and fastest-growing demographic in the U.S. In total, approximately 70 services are covered by the broad scope of this agreement including: ABC, ABC Family, Disney Channel, Disney Junior, Disney XD, ESPN, ESPN2, ESPNU, ESPN Deportes, ESPNEWS, ESPN Classic, ESPN Goal Line, ESPN Buzzer Beater, ESPN 3D, ESPN GamePlan, ESPN Full Court, ESPN3, The Longhorn Network, and retransmission consent for WABC-TV, KABC-TV, WLS-TV, KGO-TV, KTRK-TV, WTVD-TV and KFSN-TV, as well as more than 10 high-definition networks.

Charter customers will receive broad access to existing authenticated products like WATCH Disney Channel, WATCH Disney XD and WATCH Disney Junior, the to-be-launched WATCH ABC and WATCH ABC Family services and WatchESPN (ESPN, ESPN2, ESPN3, ESPNU, ESPN Goal Line and ESPN Buzzer Beater). These products will give Charter customers more opportunities to access live and video on demand content, both in-home and out-of-home, on their computers, smartphones, tablets and gaming consoles.

“This agreement enables us to offer our customers additional value, choice and convenience,” said Allan Singer, Charter’s Senior Vice President, Programming. “More and more content is being enjoyed on tablets and other Internet-connected devices, and today’s viewers are sharing their TV experiences in new ways. Our agreement with Disney enables more robust ways to enjoy and socialize TV.”

Added David Preschlack, executive vice president, Affiliate Sales and Marketing, Disney & ESPN Networks Group, “Our agreement with Charter represents the sixth top ten distributor renewal encompassing Disney’s full suite of products and services. With this deal, Charter’s video customers will derive even greater benefit from the value of their multichannel subscription model, including 24/7 live access to our content via the WATCH Disney services and WatchESPN across more platforms than ever before, as well as other new and advanced services.”

The extensive and expanded rights package for Video On Demand content to Charter TV customers includes:

• ABC On Demand, ABC’s fast-forward-disabled On Demand service, which currently features a selection of top-rated primetime entertainment programming, including episodes of such popular current ABC shows as “Castle,” “Grey’s Anatomy,” “Once Upon A Time,” “Private Practice” and “Revenge.” Full current seasons will be made available on a number of shows.
• ABC Family On Demand, which features a variety of top-rated full episodes, refreshed monthly, from such popular millennial favorites as “Switched at Birth,” “The Secret Life of the American Teenager,” “Baby Daddy,” “Bunheads” and “Melissa & Joey.” Full current seasons will be made available on a number of shows. ABC Family original movies like “Mistle-Tones” will also be available.
• Disney-branded On Demand offerings, including Disney Channel On Demand, Disney Junior On Demand, and Disney XD On Demand. Refreshed each month, the Disney Channel On Demand offering will include episodes from such series as “Handy Manny,” “Mickey Mouse Clubhouse,” and “Jake and the Never Land Pirates” for preschoolers, as well as variety of episodes from “A.N.T. Farm,” “Good Luck Charlie,” “Jessie,” and other popular series for older kids. Select episodes featured on Disney Channel On Demand will be available in innovative new offerings, such as playlists and monthly programming blocks, in addition to a number of episodes available in multiple languages. A variety of Disney Channel Original Movies will also be available. Disney XD On Demand features a selection of episodes from such series as the Emmy Award-winning animated hit “Phineas and Ferb,” “Pair of Kings” and “Kickin’ It.”
• Expanded On Demand content from ESPN, including award-winning original content from ESPN Films.

About Charter Communications

Charter (NASDAQ: CHTR) is a leading broadband communications company and the fourth-largest cable operator in the United States. Charter provides a full range of advanced broadband services, including advanced Charter TV® video entertainment programming, Charter Internet® access, and Charter Phone®. Charter Business® similarly provides scalable, tailored, and cost-effective broadband communications solutions to business organizations, such as business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Charter’s advertising sales and production services are sold under the Charter Media® brand. More information about Charter can be found at charter.com.

About The Walt Disney Company

The Walt Disney Company (NYSE: DIS), together with its subsidiaries and affiliates, is the world’s largest diversified international family entertainment and media enterprise with five business segments: media networks, parks and resorts, studio entertainment, consumer products and interactive media. Disney Media Networks comprise a vast array of The Walt Disney Company’s broadcast, cable, radio and publishing businesses, including Disney/ABC Television Group and ESPN, Inc. Disney is a Dow 30 company and had annual revenues of $40.9 billion in its most recent fiscal year.

SORL Auto Parts (SORL) Receives High-Tech Enterprise Status and Preferred Tax Rate

– Net Income Guidance Based on 15% Tax Rate is Approximately $12.7 Million in 2012

ZHEJIANG, China, Dec. 31, 2012  /PRNewswire-FirstCall/ —SORL Auto Parts, Inc. (NASDAQ: SORL) (“SORL” or “the Company”), a leading supplier of brake and control systems to the global commercial vehicle industry, announced today that the Chinese government has renewed SORL’s High-Tech Enterprise status. The Company was also designated as a High-Tech Enterprise beginning in 2009, the first year it was available, through the 2011 fiscal year. As a High-Tech Enterprise, SORL receives a preferred tax rate of 15% for the three years 2012 through 2014, compared with the normal 25% corporate tax rate.

There are a number of criteria to qualify for the High-Tech Enterprise including: a company must own proprietary intellectual rights, operate in a government-selected industry, R&D expenditures and income from high-tech products/services each must meet a required minimum percentage of annual revenue, and the number of R&D personnel must meet a  required percentage of total employees.

The Company already has received its anticipated tax refund for the first three-quarters of 2012 of approximately $1.2 million (approximately RMB 7.64 million) resulting from this designation.

For fiscal year 2012, management reiterates its expectation for net sales to be approximately $191.4 million and revises its net income expectation to be approximately $12.7 million. The revised net income guidance is based upon the preferred 15% tax rate from the renewal of the High-Tech Enterprise status. This target is based on the Company’s current views on the operating and market conditions, which are subject to change.

Ms. Jinrui Yu, SORL Auto Parts’ COO, said, “The High-Tech Enterprise designation reflects the Chinese government’s desire to build the domestic technology base by favoring only companies that are advancing technologies. Our research and development program is innovating new products with higher technology content to offer better solutions for our customers’ current vehicles and to prepare for future vehicles, especially pure electric and plug-in hybrid vehicles promoted by the Chinese government. Innovation will enable us to sustain our leading position in the domestic market for brake systems and better penetrate the global auto parts industry to gain momentum for our future growth, strengthen our technology base and build shareholder value.”

About SORL Auto Parts, Inc.

As a global tier one supplier of brake and control systems to the commercial vehicle industry, SORL Auto Parts, Inc. is the market leader for commercial vehicles brake systems, such as trucks and buses in China. The Company distributes products both within China and internationally under the SORL trademark. SORL is listed among the top 100 auto component suppliers in China, with a product range that includes 65 categories with over 2000 specifications in brake systems and others. The Company has four authorized international sales centers in UAE, India, the United States and Europe. SORL is working to establish a broader global sales network. For more information, please visit http://www.sorl.cn .

Safe Harbor Statement

This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “believes”, “expects” or similar expressions. These forward-looking statements may also include statements about the Company’s proposed discussions related to its business or growth strategy, which are subject to change. Such information is based upon expectations of the Company’s management that were reasonable when made, but may prove to be incorrect. All of such assumptions are inherently subject to uncertainties and contingencies beyond the Company’s control and upon assumptions with respect to future business decisions, which are subject to change. The Company does not undertake to update the forward-looking statements contained in this press release. For additional information regarding known material factors that could cause the Company’s results to differ from its projected results, please see its filings with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov .

Contact Information

Raymond Lin
+86 13967776556
+ 86 577 65817721
Email: ljf@sorl.com.cn

Phyllis Huang
+86 15167705972
+86 577 65817721
Email: Phyllis@sorl.com.cn

Kevin Theiss
Grayling
+1 646 284 9409
Email: kevin.theiss@grayling.com

On Track (OTIV) Announces Results of December 30 Extraordinary General Meeting

ROSH PINA, Israel, Dec. 31, 2012 (GLOBE NEWSWIRE) — On Track Innovations Ltd. (“OTI“) (Nasdaq:OTIV), a global leader in contactless microprocessor-based smart card solutions for homeland security, payments, eID Systems and other applications, reports that the extraordinary general meeting of shareholders that was held on December 30, 2012 approved the election of Ms. Eileen Segall and Mr. Jeffrey E. Eberwein to serve as external directors of OTI for a three-year term starting on the date of the meeting and the election of Mr. Charles M. Gillman, Mr. Dilip Singh, Mr. Richard Kenneth Coleman, Jr., Mr. Mark Stolper, Mr. Dimitrios Angelis and Mr. John Knapp to serve as directors of OTI until the first general meeting of the shareholders of OTI to be held following the termination of a 36 months period commencing as of the date of the meeting.

About On Track Innovations Ltd. (www.otiglobal.com)

On Track Innovations Ltd. (“OTI”) designs, develops and markets ID-credentialing, payment and loyalty applications based on its extensive patent and IP portfolio. OTI combines standards-compliant and state-of-the-art, contactless microprocessor-based technologies and enabling hardware with proprietary software applications to deliver high performance, end-to-end solutions that are secure, robust and scalable. OTI solutions have been deployed around the world to address homeland security, national ID, medical ID, contactless payment and NFC solutions, loyalty applications, petroleum payment, parking and mass transit ticketing. OTI markets and supports its solutions through a global network of regional offices and alliances.

The On Track Innovations Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5736

The content of OTI’s website mentioned above is not part of this press release.

CONTACT: OTI Contacts:
         Galit Mendelson
         VP, Corporate Relations
         732 429 1900 ext. 111
         galit@otiglobal.com

         Media Relations:
         Joe McGurk/Elizabeth Austin
         KCSA Strategic Communications
         212.896.1241/212.896.1231
         jmcgurk@kcsa.com/eaustin@kcsa.com

         Investor Relations:
         Todd Fromer / Garth Russell
         KCSA Strategic Communications
         212-896-1215 / 212-896-1250
         tfromer@kcsa.com /grussell@kcsa.com

LifeVantage (LFVN) to Present at the Sidoti Semi-Annual Micro-Cap Conference

SALT LAKE CITY, Dec. 31, 2012 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim^®, the Nrf2 Synergizer^®, announced today that Douglas C. Robinson, the Company’s President and Chief Executive Officer, and David Colbert, the Company’s Chief Financial Officer, will be presenting at the Sidoti Semi-Annual Micro-Cap Conference to be held on January 7, 2013, at the Grand Hyatt Hotel in New York City.

The LifeVantage Corporation investor presentation is scheduled for Monday, January 7, 2013, at 8:00 am Eastern Time.

About LifeVantage Corporation

LifeVantage (Nasdaq:LFVN), a leader in Nrf2 science and the maker of Protandim^®, the Nrf2 Synergizer^® patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, UT.

The LifeVantage Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11617

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

(OBJE) Targets High-Growth Mobile Gaming App Market With Phantasmic

With the first gaming app produced by OBJ Enterprises’ (OTCBB: OBJE) joint venture with Source Street, LLC, entering beta testing before the end of the year, the company anticipates a successful launch in 2013 that will capture a lucrative slice of the booming mobile gaming market.

According to recent figures by the mobile analytics firm Flurry, mobile apps for Apple (NASDAQ: AAPL) iPhone and iPad as well as Google (NASDAQ: GOOG) Android devices generated about $10 billion in revenue this year—an incredible 80 percent of which came from gaming apps. In fact, gaming apps dominate all other mobile categories, with users spending 43 percent of their app time on games.

“The incredible financial success of gaming apps in 2012 and beyond is a tribute to the power of the ‘freemium’ business model,” said OBJE CEO Paul Watson. “Mobile games are driving the growth in the multi-billion-dollar global video game industry, and free-to-play apps represent the most prolific sector in this new era of digital distribution.”

Novalon Games, the gaming developer founded by the joint venture of OBJE and Source Street, is set to begin beta testing Phantasmic, the first of two brand new iOS gaming apps scheduled for a 2013 release. Gaming apps like Phantasmic give consumers free access to the core of a game, but charge for virtual items and power-ups through micro-transaction.

The game maker is also developing Wayfarers, a sophisticated online roleplaying game, for release in the coming year as well.

Obscene Interactive is a division of OBJ Enterprises, Inc. that is working to develop innovative products to service the fast-growing social gaming sector alongside companies such as Glu Mobile Inc. (NASDAQ: GLUU), The9 Limited (NASDAQ: NCTY) and Majesco Entertainment Co. (NASDAQ: COOL).

Follow OBJ Enterprises on Twitter at www.twitter.com/OBJEnterprises.

About Obscene Interactive

Obscene Interactive, a subsidiary of OBJ Enterprises, Inc. (OTCBB: OBJE), is an emerging global developer of social gaming applications. OBJE’s cutting-edge technology platform enables its titles to be accessible to a broad audience of consumers all over the world, supporting multiple platforms for universal appeal. Obscene Interactive is focused on delivering the best in social gaming solutions to the mass market. For investment information and performance data, please visit www.ObsceneInteractive.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Mid Penn Bancorp (MPB) Repurchases Its Entire $10 Million of Preferred Stock Issued Under TARP

Mid Penn Bancorp, Inc. Repurchases Its Entire $10 Million of Preferred Stock Issued Under TARP Capital Purchase Plan

MILLERSBURG, Pa., Dec. 28, 2012 (GLOBE NEWSWIRE) — The Board of Directors of Mid Penn Bancorp, Inc. (“Mid Penn”) (Nasdaq:MPB) today proudly announced that it has repurchased and redeemed all of its Series A Preferred Stock that was issued to the U.S. Treasury under the TARP Capital Purchase Program. Mid Penn repurchased the preferred stock for a price equal to the aggregate liquidation amount of $10 million, plus accrued but unpaid dividends of $59,722.22.

The redemption will eliminate approximately $500,000 in annual preferred dividends Mid Penn has paid on the preferred stock since its issuance.

“We are pleased and proud to make this announcement and we believe that our full repayment to TARP validates the strength and stability of Mid Penn,” said President and CEO Rory G. Ritrievi. “The CPP program, instituted by the United States Treasury in 2008, allowed qualifying banks the opportunity to effectively stay in the lending business. Now, four years later, we feel it is in the best interests of our shareholders to thank the Federal Government by repaying that investment in full, even after paying all preferred dividends due over time. Mid Penn is in a position to do this as a result of successful years of income and capital preservation in 2010, 2011 and 2012.”

In conjunction with Mid Penn’s participation in TARP, in 2008 it issued to the U.S. Treasury a warrant to purchase up to 73,099 shares of common stock. Currently, Mid Penn intends to repurchase this warrant from the U.S. Treasury.

About Mid Penn Bank

Mid Penn Bank, a subsidiary of Mid Penn Bancorp, Inc. (Nasdaq:MPB), has been serving Central Pennsylvania since 1868. Headquartered in Millersburg, Pa., Mid Penn Bank has 14 retail locations in Cumberland, Dauphin, Northumberland and Schuylkill Counties. The bank offers a diverse portfolio of products and services to meet personal and business banking needs of the community. To learn more about Mid Penn Bank, visit midpennbank.com.

The Mid Penn Bancorp, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6428

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

Certain of the matters discussed in this press release may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and as such may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Mid Penn to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, and similar expressions are intended to identify such forward-looking statements.

Mid Penn’s actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation:

• The effects of future economic conditions on Mid Penn and its customers;
• Governmental monetary and fiscal policies, as well as legislative and regulatory changes;
• The effect of changes in accounting policies and practices, as may be adopted by the regulatory agencies, as well as the Financial Accounting Standards Board and other accounting standard setters;
• The risks of changes in interest rates on the level and composition of deposits, loan demand, and the values of loan collateral, securities and interest rate protection agreements, as well as interest rate risks;
• The effects of economic deterioration on current customers, specifically the effect of the economy on loan customers’ ability to repay loans;
• The effects of competition from other commercial banks, thrifts, mortgage banking firms, consumer finance companies, credit unions, securities brokerage firms, insurance companies, money market and other mutual funds and other financial institutions operating in Mid Penn’s market area and elsewhere, including institutions operating locally, regionally, nationally and internationally, together with such competitors offering banking products and services by mail, telephone, computer and the internet;
• The costs and effects of litigation and of unexpected or adverse outcomes in such litigation;
• Technological changes;
• Acquisitions and integration of acquired businesses;
• The failure of assumptions underlying the establishment of reserves for loan and lease losses and estimations of values of collateral and various financial assets and liabilities;
• Acts of war or terrorism;
• Volatilities in the securities markets; and
• Deteriorating economic conditions.

All written or oral forward-looking statements attributable to Mid Penn are expressly qualified in their entirety by these cautionary statements.

CONTACT: Rory G. Ritrievi
         (717) 692-7103
         rory.ritrievi@midpennbank.com